Loading...
Market
Which major pharmaceutical company will Immuneering partner with by December 31, 2024?
3
Resolution / Starting Odds
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Official announcements from Immuneering or the partnering pharmaceutical company
Story
Immuneering ($IMRX) Announces Positive Phase 2a Data for Pancreatic Cancer Drug
Sep 14, 2024, 07:02 AM
Immuneering has announced positive initial Phase 2a data for its drug IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients. The data includes both complete and partial responses, indicating promising efficacy for the treatment. This development is a significant step forward in the fight against pancreatic cancer. The drug is listed under the ticker $IMRX.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Merck • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
